Glenn N. Levine et al. JACC 2016;68:

Slides:

Advertisements

Similar presentations

Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.

Advertisements

A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.

Disease State Platelet Presentation Volume 2 Presented By: Name.

Acute Coronary Syndromes SIGN 93. MINAP Mortality after Acute Coronary Syndromes Cumulative: 13.6% Blue 10.6% Green 11.6% Red.

GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic Updates (CMS164) Change Review Process Meeting November 19, 2015 Jenna Williams-Bader.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiovascular Imaging Research at the Crossroads.

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.

Date of download: 7/7/2016 From: Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American.

Supplementary Appendix Thrombotic Risk Scores % of Patients Risk Categories Low Risk (n=3491) Intermediate Risk (n=2806)

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2014 AHA/ACC Guideline for the Management of Patients.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effectiveness of In-Laboratory High-Dose Clopidogrel.

The Primary and Secondary Prevention of Cardiovascular Disease

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Successful CTO PCI Associated with Lower Mortality Risk

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Ischaemic Heart Disease Acute Coronary Syndrome

Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Achieving Long-Term Protection Post-MI

Glenn N. Levine et al. JACC 2016;68:

Development of Clinical Practice Guidelines in the Care of People With Kidney Disease: Core Curriculum 2016 Angela C. Webster, PhD, Evi V. Nagler, MD,

Clyde W. Yancy et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Terms of Use. Terms of Use.

Section F: Clinical guidelines

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease Glenn N. Levine, MD, FACC, FAHA,

Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

Peter K. Smith, MD The Annals of Thoracic Surgery

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES

% Heparin + GPI IIb/IIIa Bivalirudin +

Defining operative mortality: Impact on outcome reporting

Appropriateness of Coronary Revascularization for Patients Without Acute Coronary Syndromes Edward L. Hannan, PhD; Kimberly Cozzens, MA; Zaza Samadashvili,

Risk Stratification and Interventional Cardiology: Robert L

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

John A. Bittl et al. JACC 2016;68:

Nat. Rev. Cardiol. doi: /nrcardio

P. Michael Grossman et al. JCIN 2009;2:

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Roberta Rossini et al. JCIN 2018;11:

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome.

Jeffrey L. Anderson et al. JACC 2007;50:e1-e157

Glenn N. Levine et al. JACC 2011;58:e44-e122

Lee A. Fleisher et al. JACC 2014;64:e77-e137

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Leslee J. Shaw et al. JIMG 2010;3:

Filippo Crea, and Giovanna Liuzzo JACC 2013;61:1-11

Davide Capodanno et al. JCIN 2009;2:

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization Lorenzo Azzalini,

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Presentation transcript:

Glenn N. Levine et al. JACC 2016;68:1082-1115 Treatment Algorithm for Management and Duration of P2Y12 Inhibitor Therapy in Patients Undergoing CABG Colors correspond to Class of Recommendation in Table 1. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. *Duration of DAPT therapy can vary from as little as 4 weeks to >12 months, depending on the clinical setting and bleeding risk. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; NSTE-ACS, non–ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention; post-op, postoperatively; SIHD, stable ischemic heart disease; and S/P, status post. Glenn N. Levine et al. JACC 2016;68:1082-1115 2016 American College of Cardiology Foundation and the American Heart Association, Inc.